Overview: Comprehensive Health Male Panel
Introduction: The Comprehensive Health Male Panel is a diagnostic tool designed for comprehensive male health screening using serum samples. In India, men face high NCD burden (diabetes ~15 percent, dyslipidemia, hypertension, prostate cancer, thyroid issues), with underdiagnosis in rural/low-SES groups, limited preventive care access, and rising lifestyle diseases. Symptoms may be silent early, but complications include cardiovascular events, infertility, or malignancy. Per preventive medicine practices aligned with ICMR/NCD guidelines, the test employs spectrophotometry for markers over 1-2 days with high sensitivity/specificity, valuable for annual male screening. This diagnostic falls under routine health check and targets adult males, addressing early detection of metabolic/endocrine risks to guide lifestyle or treatment. With high morbidity from underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing NCD burden in men. Its serum-based approach ensures reliable screening in India's diverse settings.
Other Names: Health Male Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.
Historical Milestone: Gender-specific preventive packages; in India, promoted with men's health initiatives.
Purpose: The test screens for 6 parameters including fasting glucose to guide comprehensive male health assessment, detect early NCD risks, inform interventions.
Test Parameters: 1. Fasting Glucose, 2. Total Cholesterol, 3. Creatinine, 4. PSA, 5. TSH, 6. CBC.
Pretest Condition: Fasting 10-12 hours required; patients should report any symptoms or family history of NCDs.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on lifestyle, prostate symptoms, thyroid issues, family NCD history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated NCDs including prostate or cardiovascular complications, benefits of early detection, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage, hemolysis, or recent meals can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate possible NCD risks, necessitating further investigation. Normal may require follow-up in high-risk individuals.
Specialist Consultation: General physicians or urologists should be consulted for interpretation and counseling.
Additional Supporting Tests: Full lipid profile, HbA1c, or testosterone for confirmation.
Test Limitations: May miss early subclinical disease or require repeat screening; comprehensive approach required.
References: ICMR NCD Guidelines 2023, Men's Health Studies India 2024.
